The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] (ICPSR 36575)

Published: Aug 8, 2017

Principal Investigator(s):
Samuel R. Friedman, National Development & Research Institute, Inc.

https://doi.org/10.3886/ICPSR36575.v1

Version V1

CVAR

The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] study (CVAR) was a research study of why large United States Metropolitan Statistical Areas (MSAs) vary over time in their vulnerability to HIV/AIDS among drug users and in MSA responses to HIV/AIDS. This collection contains estimates of HIV prevalence among people who injected drugs (PWID) and among sub-populations of PWID. This collection is comprised of ten datasets with differing amounts of variables and provides trend data that describe the following:

  • Epidemiologic outcomes including population prevalence of PWIDs and Non-injecting drug users (NIDUs), and particularly their prevalence among youth; and, among PWIDs, HIV prevalence, late-diagnosis HIV cases, and AIDS incidence and mortality.
  • Implementation of evidence-based drug-related interventions including drug abuse treatment, syringe exchange, HIV counseling and testing.
  • Implementation of non-evidence-based drug-related interventions including incarceration and arrests of drug users.

The collection contains data on the MSA sub-populations including Black, Hispanic, White and "other" race categories. In addition, some statistics are presented in age range categories such as ages 15-29, 30-64 and 15-64.

Friedman, Samuel R. The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States]. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2017-08-08. https://doi.org/10.3886/ICPSR36575.v1

Export Citation:

  • RIS (generic format for RefWorks, EndNote, etc.)
  • EndNote

United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse (5 R01 DA013336 15)

North Carolina   Milwaukee   Indiana   Ocean (New Jersey)   Fort Worth   Cincinnati   Austin   Monmouth (New Jersey)   Utah   San Jose   Rock Hill   Gastonia   San Diego   Columbus (Ohio)   Syracuse   Springfield (Massachusetts)   North Little Rock (Arkansas)   Arizona   Las Vegas   Springfield (Ohio)   Arlington   Boston   San Bernardino   Providence   Seattle   Kentucky   St. Petersburg   Bethlehem   Niagara Falls (New York)   Nashville   California   Florida   Delaware   Hunterdon (New Jersey)   Boca Raton (Florida)   Troy   Knoxville   Mississippi   Fresno   New Haven   Sarasota   Illinois   Newark   Georgia   Little Rock   Virginia   Maryland   Norfolk   Virginia Beach   Suffolk County (New York)   United States   Oklahoma   Grand Rapids   Louisville   Waukesha (Wisconsin)   Arkansas   South Carolina   Washington   Albany (New York)   Wichita   Mesa (Arizona)   Carlisle (Pennsylvania)   Fall River   Massachusetts   Missouri   Winston-Salem   Holland (Michigan)   New Orleans   Scranton   Salt Lake City   Denver   Harrisburg   St. Louis   Dallas   Nevada   Schenectady   Allentown   Raleigh   San Antonio   Muskegon   St. Paul   Clearwater   Hawaii   Passaic   Rochester (New York)   Ventura (California)   Birmingham   Michigan   Lebanon   Baltimore   New Mexico   Orlando   Louisiana   Toledo   Middlesex (New Jersey)   Philadelphia   Riverside   Akron   Oklahoma City   Greensboro   Detroit   Charlotte   High Point   Tucson   Albuquerque   Everett   Oakland   Bakersfield   New York City   Somerset (New Jersey)   Petersburg   Memphis   Ogden   Jacksonville   Buffalo   Pittsburgh   Nassau (New York)   Orange County (California)   Sacramento   El Paso   Greenville   Kansas   Meriden   Pennsylvania   Tulsa   Chapel Hill (North Carolina)   West Palm Beach   Iowa   Texas   Lorain   Portland (Oregon)   Hazleton   Tampa   Durham   San Marcos (Texas)   Indianapolis   Richmond   Oregon   Warwick   Bergen (New Jersey)   Newport News   Ann Arbor   Alabama   Cleveland   Dayton   Nebraska   Omaha   Warren   West Virginia   Elyria   Tacoma   Minneapolis   Youngstown   Atlanta   Honolulu   Phoenix   Bradenton   Wilmington (Delaware)   Gary   Rhode Island   District of Columbia   Vancouver (Washington)   Lodi (California)   Chicago   Fort Lauderdale   Wilkes-Barre   Minnesota   Kansas City (Missouri)   Bellevue   New York (state)   Anderson   New Jersey   Miami   San Francisco   Charleston (South Carolina)   Jersey City   Long Beach   Spartanburg (South Carolina)   New Hampshire   Easton   Ohio   Los Angeles   Hartford   Stockton   Houston

Metropolitan Statistical Area

1990 -- 2013

Some of the data used to contruct the datasets for this study are available through NAHDAP. See the following links for more information on the N-SSATS and TEDS studies:

The MSA variable is present in all 10 datasets and represents the Metropolitan Statistical Area Federal Information Processing Standards (Fips) code. This variable can be used to link data between datasets. However, be advised that MSA is not a unique identifier within all datasets. Therefore, users should take care to transform the necessary variables before merging datasets.

This study was conducted to help understand the forces that shape metropolitan area HIV/AIDS epidemics and prevention programs and provide data to inform future policy making decision regarding HIV/AIDS. The study data are intended to provide information on several relationships including:

  • How epidemiologic need and macro-social contexts such as economic changes, social integration, and residential segregation by race affect interventions.
  • How interventions and macro-social contexts together affect epidemiologic contexts.
  • How some interventions (e.g., arrests, incarceration) affect others (e.g., syringe exchange coverage).
  • How some epidemiologic outcomes (e.g., prevalence of young IDUs) affect others (e.g., HIV prevalence).

Longitudinal trend data on 96 Metropolitan Statistical Areas in the United States were compiled from secondary sources to provide information on epidemiologic factors, evidence based interventions, and non-evidence based intervention that contribute to changes in community vulnerability to drug-user-related HIV/AIDS. The principal investigators used these data to create novel variables.

Some of the secondary data sources used include:

For more information please see the following articles and the data documentation.

Tempalski, B., Pouget, E.R., Cleland, C.M., Brady, J.E., Cooper, H.L.F., Hall, H.I., Lansky, A., West, B.S., Friedman, S.R. Trends in the population prevalence of people who inject drugs in US Metropolitan Areas 1992-2007. PLoS ONE 2013. Vol. 8. No. 6. e64789.

Chatterjee, S., Tempalski, B., Pouget, E.R., Cooper, H.L.F., Cleland, C.M., Friedman, S.R. Changes in the Prevalence of Injection Drug Use Among Adolescents and Young Adults in Large U.S. Metropolitan Areas. AIDS and Behavior July 2011. Vol. 15, No.7, pp.1570-1578. DOI: 10.1007/s10461-011-9992-0

For information on the Metropolitan Statistical Area sampling, see the following article.

Tempalski, B., Lieb, S., Cleland, C.M., Cooper, H., Brady, J.E., Friedman, S.R. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, (1992-2002). Journal of Urban Health 2009. Vol. 86, pp. 132-54.

Longitudinal

Metropolitan Statistical Areas in the United States

Metropolitan Statistical Area

administrative records data

aggregate data

census/enumeration data

See the variable description by dataset below:

  • DS1: Contains demographic variables including total and percentage of the population by race and age categories over the period from 1990-2013.
  • DS2: Contains the annual number of treatment episodes where admission documentation indicate that any substance was injected intravenously or intramuscularly from 1992-2004. These data include admissions by client attribute. Further detail is provided on types of admissions.
  • DS3: Contains the number and rates at of people who injected drugs (PWID) each year between 1993-2002.
  • DS4: Contains treatment coverage rates from 2000-2008 for alcohol and substance abuse.
  • DS5: Contains the number of injecting drug users (IDUs) and non-injecting drug users (NIDUs) by race over the period from 1992-2007.
  • DS6: Contains number of people with injecting drug use (PWID) by sub-population annually between 1992-2007.
  • DS7: Contains the injecting drug user rate among young people between 15-29 years old over the period between 1992-2002.
  • DS8: Contains data on drug related arrest rates, Uniform Crime Reporting (UCR) counts, and the number of murders by year between 1991-2009.
  • DS9: Contains estimate of HIV prevalence rates among people who inject drugs each year from 1992-2002.
  • DS10: Contains poisoning and drug mortality rates by year between 1993-2007.

Not Applicable

None

2017-08-08

2017-08-08

2017-08-08 ICPSR data undergo a confidentiality review and are altered when necessary to limit the risk of disclosure. ICPSR also routinely creates ready-to-go data files along with setups in the major statistical software formats as well as standard codebooks to accompany the data. In addition to these procedures, ICPSR performed the following processing steps for this data collection:

  • Standardized missing values.
  • Checked for undocumented or out-of-range codes.

Notes

  • The public-use data files in this collection are available for access by the general public. Access does not require affiliation with an ICPSR member institution.

NAHDAP logo

This study is maintained and distributed by the National Addiction & HIV Data Archive Program (NAHDAP). NAHDAP is supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH).